Journal
CANCER CELL
Volume 31, Issue 2, Pages 172-179Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2017.01.002
Keywords
-
Categories
Funding
- European Community [602901, 635342-2, 115749]
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille Ministero della Salute
- AIRC Special Program Molecular Clinical Oncology 5 per mille [9970]
- AIRC IG [16788]
- GOI-Merck's Grant for Oncology Innovation Research Project
- European Research Council [269081]
Ask authors/readers for more resources
The inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens. Analysis of cell-free DNA and circulating tumor cells has the potential to change clinical practice by exploiting blood rather than tissue as a source of information. Liquid biopsies are already used to monitor disease response and track the emergence of drug resistance. The suitability of blood-based molecular profiles for early detection and monitoring minimal residual disease is being evaluated. In this review, we address open questions in this fast-evolving field of research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available